MedTrace Logo

OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

NCT01182493 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2018-03-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DEVICE

Insulin Pump (Medtronic Minimed Paradigm® VEO)

The pump delivers insulin as specified by the patient

Sponsors & Collaborators

  • Medtronic Diabetes

    lead INDUSTRY

Principal Investigators

  • Ohad Cohen, MD · Chaim Sheba Medical Center, Tel Hashomer, Israel

  • Ignacio Conget, MD · ICMDM Hospital Clínic i, Barcelona, Spain

  • Yves Reznic, MD · CHU Côte de Nacre, France

  • Ronnie Aronson, MD · FRCPC, FACE LMC Endocrinology Centres, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2014-02-28
Completion
2014-08-31

Countries

  • United States
  • Austria
  • Canada
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • Netherlands
  • North Macedonia
  • Serbia
  • South Africa
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01182493 on ClinicalTrials.gov